Three Years On, MBBS In Hindi Slow To Take Off In Madhya Pradesh
But when NDTV visited Gandhi Medical College in Bhopal, the state's premier government medical institute, the picture was more complex. "I studied in Hindi... but gave the exam in English," says Ankit Pandey, a second-year MBBS student. "No one stopped us from using Hindi, but everyone around us slowly shifted to English for better marks, for a better future."
Ankit, like many others, comes from a Hindi-medium background. He entered the college thinking this experiment would bridge the language gap. But soon, reality hit: technical terms in Hindi were awkward, exam patterns still leaned towards English, and career prospects still demanded English proficiency.
"This isn't about preference, it's about survival," adds Daksh, another student. "If I want to go for my post-graduation or work in a metro city, English is essential. If I only study in Hindi, I'll be a doctor trapped in a regional bubble."
The government spent Rs 10 crore to print Hindi medical books, distribute them across libraries, and set up translation panels. "The books are available. But I haven't seen a single student take their Physiology exam in Hindi," says Dr Rakesh Malviya, President of the Medical Teachers' Association.
The reason? It's not that students are rejecting the language, they are just unsure whether the system will reward it. There's no separate Hindi-medium form. No clear data. And, in an exam-driven profession, no one wants to risk uncertainty.
Kavita Singh, Dean of Gandhi Medical College in Bhopal, said: "15-20% of students come from Hindi medium backgrounds. They struggle at first. But most eventually shift to English to keep up."
In smaller towns like Jabalpur and Satna, however, the story is different. Here, students are actually writing exams in Hindi and doing well. Chetna Jharia, from Netaji Subhash Chandra Bose Medical College, says: "I gave the first-year exam in Hindi. When the books came in my language, I finally started understanding."
Sheetal Kori, a student at Hitkarini Dental College, recalled, "When the question came in Hindi, I could answer freely. Earlier I used to lag behind, now I feel confident."
But these success stories are a fairly small percentage of the total.
The Vice Chancellor of the Madhya Pradesh Medical Science University, Dr Ashok Khandelwal, said, "We don't have exact numbers. Some colleges say 10-15% took theory exams in Hindi. Others say 50% used mixed language in practicals. But no comprehensive data exists."
Government's Take
Rajendra Shukla, Minister of Public Health & Medical Education, said, "Nearly 15 to 20 per cent of students are studying using a mix of Hindi and English, and they're doing quite well with it."
Dr Lokendra Dave, nodal officer of the Hindi Cell, said the language is not being enforced on anybody.
"This is a trust-building step. We're not enforcing Hindi. We're just creating space for it. A student should not be judged by the language they write in," he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
21 minutes ago
- The Hindu
RSS arm seeks clarity on draft guidelines on biosimilars
Swadeshi Jagran Manch (SJM), economic wing of the Rashtriya Swayamsewak Sangh (RSS), urged the Central Drugs Standard Control Organisation (CDSCO), the apex drug regulatory authority, to bring more clarity in its draft guidelines to ensure production of high-quality and cost-effective biosimilars in the country. In a letter to the Director General of CDSCO, SJM sought safeguards for the Indian industry from 'international pressures for regulations' that favour multi-national pharma companies. The CDSCO had recently issued the 2025 draft guidelines on similar biologics, also called biosimilars. 'Though the draft guidelines represent a pivotal advancement in making affordable, life-saving biosimilars accessible to millions of Indians suffering from chronic and life-threatening conditions such as cancer, diabetes, and autoimmune disorders it requires more clarity and direction,' the SJM letter reads. The SJM appreciated the draft guidelines for embracing the '3Rs principle' (replacement, reduction, refinement) as it reflects India's commitment to ethical scientific practices and alignment with global standards for animal welfare. Modern technologies, including in-vitro assays, organ-on-chip models, and computational simulations, provide robust, accurate, and humane alternatives to confirm the safety and biosimilarity of these drugs, it said. 'These methods are often faster and more precise than animal studies, reducing both ethical concerns and development costs,' it added. The organisation, however, noted that the guidelines stipulating that it will be the discretion of the CDSCO to decide whether a requirement of 'additional non-clinical in vivo animal studies' should be waived or not, poses a 'risk' of increasing biosimilar development cost. This provision goes against the practices of the leading regulatory authorities in other countries, it added. 'Prominent regulatory authorities like the UK MHRA, European Medicine Agency (EMA) Health Canada, and USFDA have either eliminated or phased out mandatory animal testing for biosimilars,' SJM said, adding its recommendation that waiving animal studies entirely when comprehensive laboratory tests demonstrate high similarity between a biosimilar and its reference product. Recently, civil societies, in a letter to CDSCO on the draft guidelines on biosimilars, has urged that there is an urgent need to eliminate unnecessary animal studies, and establish clear conditions for requiring comparative clinical trials for affordable biosimilars without compromising safety and efficacy. According to the SJM, the draft guidelines' provision to waive certain clinical trials when biosimilarity is established through analytical and functional studies is a forward-thinking measure, saying this approach can significantly reduce development costs and expedite market entry, which is critical for patients awaiting affordable treatments. However, the lack of explicit criteria in the guidelines for when waivers are permitted introduces ambiguity, potentially leading to inconsistent application and delays as well as 'room for corrupt practices', it said, stressing the need to establish 'clear conditions' for conduct of clinical trials.
Economic Times
3 hours ago
- Economic Times
Medtech firms flag inflated MRPs on imported devices
Indian manufacturers of medical devices have alleged that several private hospitals and retailers, in the chase for higher margins, are pushing sales of imported products, some of which carry inflated price tags or do not mention the maximum retail price (MRP). These imported devices of established brands account for about 65% of the medical devices sold in India, according to industry matter was discussed at a recent meeting with commerce and industry minister Piyush Goyal, industry executives told ET."It has been seen that the private hospitals and retailers preferentially push imported medical devices, often labelled with inflated or absent MRPs," a senior industry executive who attended the meeting told ET. "The hospitals are doing this to earn higher trade margins compared to affordable Indian made devices." The executive did not wish to be the meeting, representatives of domestic manufacturers discussed the procurement challenges the industry is facing in this regard. "They are making higher margins and more money. The consumer would bear the brunt and, hence, this issue was discussed during the meeting. The ministry has asked the NPPA (National Pharmaceutical Pricing Authority) to look into the matter," said another executive, requesting not to be named. Rajiv Nath, forum coordinator of Association of Indian Medical Device Industry (AiMeD), said domestic manufacturers face a stiff challenge in the market from imported devices despite offering the same product at rates that are 20-40% less, "as private hospitals and retailers are preferentially pushing imported established brands of medical devices, often carrying inflated prices or at times labels even without MRPs"."Indian manufacturers are forced to hike their labelled MRP to satisfy these buyers," he said domestic manufacturers have demanded that all import e-bills of lading should capture the import landed price as well as the MRP on the medical device, and any irrationally excessive MRP of 20 to 30 times of landed cost should be flagged for investigation for duty evasion and unfair trade practices.
Time of India
3 hours ago
- Time of India
Medtech firms flag inflated MRPs on imported devices
Indian manufacturers of medical devices have alleged that several private hospitals and retailers, in the chase for higher margins, are pushing sales of imported products, some of which carry inflated price tags or do not mention the maximum retail price (MRP). These imported devices of established brands account for about 65% of the medical devices sold in India, according to industry sources. The matter was discussed at a recent meeting with commerce and industry minister Piyush Goyal, industry executives told ET. Explore courses from Top Institutes in Please select course: Select a Course Category Management CXO MCA Data Science PGDM Degree Cybersecurity Technology Healthcare MBA Design Thinking Public Policy healthcare Product Management others Project Management Others Digital Marketing Operations Management Finance Artificial Intelligence Leadership Data Science Data Analytics Skills you'll gain: Duration: 11 Months IIM Kozhikode CERT-IIMK General Management Programme India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK GMPBE India Starts on undefined Get Details Skills you'll gain: Duration: 9 Months IIM Calcutta CERT-IIMC APSPM India Starts on undefined Get Details "It has been seen that the private hospitals and retailers preferentially push imported medical devices, often labelled with inflated or absent MRPs," a senior industry executive who attended the meeting told ET. "The hospitals are doing this to earn higher trade margins compared to affordable Indian made devices." The executive did not wish to be named. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now At the meeting, representatives of domestic manufacturers discussed the procurement challenges the industry is facing in this regard. "They are making higher margins and more money. The consumer would bear the brunt and, hence, this issue was discussed during the meeting. The ministry has asked the NPPA ( National Pharmaceutical Pricing Authority ) to look into the matter," said another executive, requesting not to be named. Live Events Rajiv Nath, forum coordinator of Association of Indian Medical Device Industry (AiMeD), said domestic manufacturers face a stiff challenge in the market from imported devices despite offering the same product at rates that are 20-40% less, "as private hospitals and retailers are preferentially pushing imported established brands of medical devices, often carrying inflated prices or at times labels even without MRPs". "Indian manufacturers are forced to hike their labelled MRP to satisfy these buyers," he said. Nath said domestic manufacturers have demanded that all import e-bills of lading should capture the import landed price as well as the MRP on the medical device, and any irrationally excessive MRP of 20 to 30 times of landed cost should be flagged for investigation for duty evasion and unfair trade practices.
